ResearcherKarolinska InstitutetNo recent work listed

Donald P. Cameron

ORCID-verified (high confidence, 0.95), identity_conf@1As of 9 November 2026

Matched on ORCID iD 0000-0002-3175-6965; OpenAlex author ID A5056461677. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 6

Papers, trials and grants by year

2023: 1 paper

Papers 1

Coinhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer via readthrough transcription. Co-author DOI 10.1126/sciadv.adg5109 ↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Phyllis F. Cheung · 1 shared paper, 2023 · strength 0.13
- Paper Coinhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer via readthrough tra… DOI 10.1126/sciadv.adg5109 ↗
Andrea Tannapfel · 1 shared paper, 2023 · strength 0.13
- Paper Coinhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer via readthrough tra… DOI 10.1126/sciadv.adg5109 ↗
Stephan A. Hahn · 1 shared paper, 2023 · strength 0.13
- Paper Coinhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer via readthrough tra… DOI 10.1126/sciadv.adg5109 ↗
Laura Baranello · 1 shared paper, 2023 · strength 0.13
- Paper Coinhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer via readthrough tra… DOI 10.1126/sciadv.adg5109 ↗
Jens Thomas Siveke · 1 shared paper, 2023 · strength 0.13
- Paper Coinhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer via readthrough tra… DOI 10.1126/sciadv.adg5109 ↗
Smiths Lueong · 1 shared paper, 2023 · strength 0.13
- Paper Coinhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer via readthrough tra… DOI 10.1126/sciadv.adg5109 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.